MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
5.02 M |
Market Cap[1] |
$ 5.88 M |
EBITDA (LTM) |
$ -10.5 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
-1.49 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Ascendis Pharma A/S
ASND
|
$ 216.76 | -0.6 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Longeveron
LGVN
|
$ 0.92 | -3.94 % | $ 16.2 B | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 19.33 | 0.52 % | $ 904 M | Nasdaq Global Select Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 8.32 | -1.25 % | $ 111 M | Nasdaq Global Market | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
$ 2.76 | 3.76 % | $ 5.29 M | Nasdaq Capital Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 0.69 | 13.84 % | $ 7.9 M | Nasdaq Capital Market |  Israel |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Exelixis
EXEL
|
$ 41.83 | 1.01 % | $ 11.4 B | Nasdaq Global Select Market,SPB | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.34 | -4.64 % | $ 342 M | Nasdaq Global Select Market | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Genmab A/S
GMAB
|
$ 25.78 | 0.39 % | $ 16.5 B | Nasdaq Global Select Market | Danmark |
 |
Aytu BioScience
AYTU
|
$ 2.6 | -1.14 % | $ 16.3 M | Nasdaq Capital Market | USA |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Lipocine
LPCN
|
$ 7.35 | 0.55 % | $ 38.7 M | Nasdaq Global Select Market | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.72 | 4.88 % | $ 624 M | Nasdaq Global Select Market | USA |
 |
Immatics N.V.
IMTX
|
$ 9.3 | -2.21 % | $ 585 M | Nasdaq Global Select Market | Germany |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.34 | -1.79 % | $ 832 M | Nasdaq Global Select Market | Canada |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 69.69 | -1.55 % | $ 11.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.